Spire Inc. (NYSE: SR) today reported results for its fiscal year 2025 ended September 30. Highlights include: Fiscal 2025 ...
Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback